Fig. 1 · Structure

Documents & Downloads

Betamethasone dipropionate

Cat. No. A10130 CAS 5593-20-4

Glucocorticoid Receptor Agonist

Betamethasone dipropionate is a glucocorticoid steroid with anti-inflammatory and immunosuppressive abilities.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Macrophage experiments associate betamethasone dipropionate with reduced pro-IL-1β expression and p65 phosphorylation. RU486 partly reversed inhibition. Separate overexpression and lysate assays found no detectable disruption of tested NLRP3 interactions or protease protection; endogenous assembly effects remain unresolved. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Glucocorticoid receptor

Betamethasone dipropionate Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Betamethasone dipropionate from 2 published references. In vitro models include THP-1-derived macrophages and mouse BMDMs.

Betamethasone dipropionate In Vitro Studies

Betamethasone dipropionate suppressed stimulated IL-1β secretion in THP-1-derived macrophages and mouse BMDMs, with reported IC50 values of 0.0029 and 0.0047 μM, respectively. These are cellular secretion endpoints. [1]

Macrophage IL-1β dose response and viability controls

Cell-based study · THP-1-derived macrophages and C57BL/6 mouse bone marrow-derived macrophages (BMDMs) [1]

BD reduced stimulated IL-1β secretion. Viability was assessed separately at higher concentrations and longer exposure; CC50 values are not therapeutic indices.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Secreted IL-1β in stimulated THP-1-derived macrophagesIC50 0.0029 μM[1]
Secreted IL-1β in stimulated BMDMsIC50 0.0047 μM[1]
Cell viability after 24 hCC50 THP-1: 285.3 μM; BMDMs: 318.9 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
IL-1β assay: 10^-3–1 μM; viability assay: 2.5–320 μM
Exposure duration
BD pretreatment: 12 h in THP-1-derived macrophages and 1 h in BMDMs; viability: 24 h
Method
LPS/nigericin-stimulated secretion compared with no-BD stimulated and LPS-only controls
Vehicle
DMSO
Reported limits
Final DMSO percentage and exact biological n for Figure 1 are not specified in the reviewed caption. Section 2.9 defines n as biological replicates and technical triplicates for ELISA.
Methods and source locations

Compound reported in the paper: Betamethasone dipropionate; Compound label in the paper: BD

Reported reagent experiments; no confirmation of Adooq lot equivalence.

Section 3.1; Figure 1A–E; sections 2.1–2.4, 2.9

Secreted IL-1β in stimulated THP-1-derived macrophages: ELISA; author-reported fit — Section 3.1; Figure 1C

Secreted IL-1β in stimulated BMDMs: ELISA; author-reported fit — Section 3.1; Figure 1E

Cell viability after 24 h: CCK-8; author-reported fits — Section 3.1; Figure 1B,D

Pro-IL-1β expression and GR antagonist perturbation

Cell-based study · THP-1-derived macrophages and mouse BMDMs [1]

BD reduced pro-IL-1β transcript/protein without marked NLRP3 or caspase-1 reduction. Reduced p65 phosphorylation and partial RU486 reversal support a priming-pathway contribution; they do not establish a unique direct target.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Pro-IL-1β mRNA/protein; NLRP3 and caspase-1 proteinDirection Pro-IL-1β decreased; NLRP3 and caspase-1 not markedly downregulated[1]
p-p65/total p65 and secreted IL-1β with GR antagonistDirection p-p65 decreased; RU486 attenuated BD-associated IL-1β inhibition[1]

Literature-Reported Treatment Conditions

Treatment concentration
BD: 0.01, 0.1 and 1 μM for expression/p65; BD 1 μM with RU486 1 or 10 μM
Exposure duration
BD pretreatment: 12 h (THP-1-derived cells) or 1 h (BMDMs); RU486 15 min before BD
Method
Stimulated macrophage expression assays and antagonist perturbation
Vehicle
DMSO
Co-treatment
RU486 only in antagonist arms
Reported limits
Final DMSO percentage and exact biological n are not specified in the reviewed figure captions. Mean ± SD per section 2.9.
Methods and source locations

Compound reported in the paper: Betamethasone dipropionate; Compound label in the paper: BD

Reported reagent experiments; no confirmation of Adooq lot equivalence.

Sections 3.3–3.4; Figures 3A–F and 4B–D; sections 2.2, 2.4–2.6, 2.9

Pro-IL-1β mRNA/protein; NLRP3 and caspase-1 protein: RT-qPCR and Western blot; GAPDH controls — Figure 3A–F; section 3.3

p-p65/total p65 and secreted IL-1β with GR antagonist: Western blot and ELISA; stimulated no-BD and BD-only comparators — Figure 4B–D; section 3.4

Negative inflammasome interaction and protease-protection tests

Biochemical assay · HEK293T overexpression system and corresponding protein-containing lysates [1]

Co-IP did not reveal disruption of tested NLRP3 interactions. DARTS did not detect protein protection. These limited negative assays do not exclude upstream or endogenous macrophage assembly effects.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NLRP3–NEK7, NLRP3–ASC and NLRP3–NLRP3 associationQualitative No disruption detected with BD 1 μM[1]
NLRP3, ASC and caspase-1 protease protectionQualitative No detectable protection with BD 50 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Co-IP: 1 μM; DARTS: 50 μM
Exposure duration
DARTS BD incubation: 60 min; Co-IP BD exposure duration not specified in reviewed methods/caption
Method
Co-IP and DARTS followed by immunoblotting
Vehicle
DMSO
Reported limits
No positive binding-ligand control is shown in Figure 5; absence of protection does not establish absence of binding.
Methods and source locations

Compound reported in the paper: Betamethasone dipropionate; Compound label in the paper: BD

Reported reagent experiments; no confirmation of Adooq lot equivalence.

Section 3.5; Figure 5A–F; sections 2.6–2.7; discussion and limitations

NLRP3–NEK7, NLRP3–ASC and NLRP3–NLRP3 association: Co-IP with input and tag controls — Figure 5A–C; section 3.5

NLRP3, ASC and caspase-1 protease protection: DARTS; DMSO and no-pronase controls — Figure 5D–F; section 3.5; section 2.7

Betamethasone dipropionate In Vivo Studies

In a mouse psoriasis-like dermatitis model, topical betamethasone dipropionate reduced ear thickening and IL-17a expression. It did not significantly suppress IL-23a, IL-22 or TNF-α expression at the tested dose. Combination with calcipotriol produced a stronger ear-thickness response than either agent alone. [2]

Single-agent and combination effects in murine psoriasis-like dermatitis

Animal study · Male BALB/c mice; imiquimod-induced ear dermatitis [2]

BDP alone modestly reduced ear thickening and IL-17a mRNA but did not significantly suppress IL-23a, IL-22 or TNF-α mRNA. The combination had a stronger ear-thickness effect; its broader cytokine effects cannot be attributed to BDP alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ear thicknessComparison BDP vs vehicle: p < 0.001; combination stronger than either monotherapy (p < 0.001)[2]
Ear-skin cytokine mRNA relative to GapdhComparison BDP reduced IL-17a (p < 0.01 vs vehicle); no significant suppression of IL-23a, IL-22 or TNF-α[2]

Conditions shared by the study groups

Route
Topical ear application
Frequency
Daily, 1 h before imiquimod
Treatment course
6 consecutive days
Vehicle
20 μL ethanol
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
BDP alone
0.06 nmol BDP
Imiquimod + ethanol vehicle; normal untreated mice; calcipotriol-only comparatorModest significant ear-thickness and IL-17a reduction; other tested cytokine transcripts not significantly suppressed.[2]
Cal/BDP
0.6 nmol calcipotriol + 0.06 nmol BDP
Imiquimod + ethanol vehicle; normal untreated mice; calcipotriol-only comparatorGreater ear-thickness reduction than either monotherapy; suppression of all four tested cytokine transcripts.[2]
BDP alone
Model: Male BALB/c mice; imiquimod-induced ear dermatitis
Cal/BDP
Model: Male BALB/c mice; imiquimod-induced ear dermatitis
Methods and source locations

Compound reported in the paper: Betamethasone dipropionate; Compound label in the paper: BDP

Reported reagent experiments; no confirmation of Adooq lot equivalence.

Results Sec4; Figure 3A–B; methods Sec10–Sec13 and Sec16

Ear thickness: Daily dial thickness gauge; mean ± SE, n = 6; Tukey test — Figure 3A; Results Sec4

Ear-skin cytokine mRNA relative to Gapdh: RT-qPCR; n = 6, individual mice with group means; similar results in two independent experiments — Figure 3B; Results Sec4; methods Sec13

BDP alone · Figure 3A–B; Results Sec4; methods Sec10

Cal/BDP · Figure 3A–B; Results Sec4; methods Sec10

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 5593-20-4
Applications Glucocorticoid Receptor Agonist
Formula C28H37FO7
Molecular Weight 504.6
Synonyms Diprospan; Diprolene; Diprosone; Diprolene AF
SMILES
CCC(=O)OCC(=O)[C@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)OC(=O)CC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 90 mg/mL (178.36 mM)
Water Insoluble
Ethanol 59 mg/mL (116.92 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Betamethasone dipropionate Research References

  1. [1] Weichen Huang, Shoufeng Xie, Xinyu Rong, et al. Betamethasone Dipropionate Inhibits NLRP3 Inflammasome Activation by Suppressing Pro-IL-1β Expression Frontiers in Bioscience-Landmark (2026). PMID: 42530265 DOI: 10.31083/FBL51536 Source material
  2. [2] Kyosuke Satake, Toru Amano, Tadao Okamoto. Calcipotriol and betamethasone dipropionate synergistically enhances the balance between regulatory and proinflammatory T cells in a murine psoriasis model Scientific Reports (2019). PMID: 31705000 DOI: 10.1038/s41598-019-52892-1 Source material

Added to your cart

View Cart Checkout
Loading...